These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 28770623)

  • 41. The potential of fibroblast growth factor/fibroblast growth factor receptor signaling as a therapeutic target in tumor angiogenesis.
    Ronca R; Giacomini A; Rusnati M; Presta M
    Expert Opin Ther Targets; 2015; 19(10):1361-77. PubMed ID: 26125971
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Antiangiogenesis beyond VEGF inhibition: a journey from antiangiogenic single-target to broad-spectrum agents.
    Limaverde-Sousa G; Sternberg C; Ferreira CG
    Cancer Treat Rev; 2014 May; 40(4):548-57. PubMed ID: 24360358
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A novel synthetic small molecule YF-452 inhibits tumor growth through antiangiogenesis by suppressing VEGF receptor 2 signaling.
    Liu Y; He Y; Yang F; Cong X; Wang J; Peng S; Gao D; Wang W; Lan L; Ying X; Liu M; Chen Y; Yi Z
    Sci China Life Sci; 2017 Feb; 60(2):202-214. PubMed ID: 28194552
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Angiogenesis in biliary tract cancer: targeting and therapeutic potential.
    Rimini M; Casadei-Gardini A
    Expert Opin Investig Drugs; 2021 Apr; 30(4):411-418. PubMed ID: 33491502
    [No Abstract]   [Full Text] [Related]  

  • 45. SB365, Pulsatilla saponin D, targets c-Met and exerts antiangiogenic and antitumor activities.
    Hong SW; Jung KH; Lee HS; Son MK; Yan HH; Kang NS; Lee J; Hong SS
    Carcinogenesis; 2013 Sep; 34(9):2156-69. PubMed ID: 23671132
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The coming of ramucirumab in the landscape of anti-angiogenic drugs: potential clinical and translational perspectives.
    Calvetti L; Pilotto S; Carbognin L; Ferrara R; Caccese M; Tortora G; Bria E
    Expert Opin Biol Ther; 2015; 15(9):1359-70. PubMed ID: 26190526
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Antiangiogenic agents and targets: A perspective.
    Teicher BA
    Biochem Pharmacol; 2011 Jan; 81(1):6-12. PubMed ID: 20920481
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584.
    Qian DZ; Wang X; Kachhap SK; Kato Y; Wei Y; Zhang L; Atadja P; Pili R
    Cancer Res; 2004 Sep; 64(18):6626-34. PubMed ID: 15374977
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Placental growth factor is a predictive biomarker for ramucirumab treatment in advanced gastric cancer.
    Natsume M; Shimura T; Iwasaki H; Okuda Y; Kitagawa M; Okamoto Y; Hayashi K; Kataoka H
    Cancer Chemother Pharmacol; 2019 Jun; 83(6):1037-1046. PubMed ID: 30899983
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Targeting VEGFR-2 in Metastatic Gastric Cancer: Results From a Literature-Based Meta-Analysis.
    Roviello G; Polom K; Roviello F; Marrelli D; Multari AG; Paganini G; Pacifico C; Generali D
    Cancer Invest; 2017 Mar; 35(3):187-194. PubMed ID: 28165839
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Emerging mAbs for the treatment of esophagogastric cancer.
    Ku GY; Ilson DH
    Expert Opin Emerg Drugs; 2015 Mar; 20(1):63-74. PubMed ID: 25483267
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Vessel pruning or healing: endothelial metabolism as a novel target?
    Cantelmo AR; Pircher A; Kalucka J; Carmeliet P
    Expert Opin Ther Targets; 2017 Mar; 21(3):239-247. PubMed ID: 28081641
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Novel drugs in clinical development for hepatocellular carcinoma.
    Waidmann O; Trojan J
    Expert Opin Investig Drugs; 2015; 24(8):1075-82. PubMed ID: 26108356
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The safety and efficacy of ramucirumab for the treatment of metastatic colorectal cancer.
    Diaz-Serrano A; Riesco-Martinez MC; Garcia-Carbonero R
    Expert Rev Anticancer Ther; 2016 Jun; 16(6):585-95. PubMed ID: 27144874
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Angiogenesis and apatinib: a new hope for patients with advanced gastric cancer?
    de Mello RA; de Oliveira J; Antoniou G
    Future Oncol; 2017 Feb; 13(4):295-298. PubMed ID: 27928929
    [No Abstract]   [Full Text] [Related]  

  • 56. Future prospects and challenges of antiangiogenic cancer gene therapy.
    Samaranayake H; Määttä AM; Pikkarainen J; Ylä-Herttuala S
    Hum Gene Ther; 2010 Apr; 21(4):381-96. PubMed ID: 20163246
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Targeting Angiogenesis in Biliary Tract Cancers: An Open Option.
    Simone V; Brunetti O; Lupo L; Testini M; Maiorano E; Simone M; Longo V; Rolfo C; Peeters M; Scarpa A; Azzariti A; Russo A; Ribatti D; Silvestris N
    Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28212293
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Neovascularization: an attractive but tricky target in thyroid cancer.
    Tasoulas J; Tsourouflis G; Theocharis S
    Expert Opin Ther Targets; 2018 Sep; 22(9):799-810. PubMed ID: 30124087
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Ramucirumab for gastric cancer.
    Shitara K; Ohtsu A
    Expert Rev Gastroenterol Hepatol; 2015 Feb; 9(2):133-9. PubMed ID: 25431958
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Investigational drugs for the treatment of cervical cancer.
    Barra F; Lorusso D; Leone Roberti Maggiore U; Ditto A; Bogani G; Raspagliesi F; Ferrero S
    Expert Opin Investig Drugs; 2017 Apr; 26(4):389-402. PubMed ID: 28274154
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.